Expansion into Five Middle Eastern Countries Including UAE, Turkiye, Saudi Arabia, and Qatar
Daewoong Pharmaceutical announced on July 25 that it has signed a contract to export its high-purity, high-quality botulinum toxin 'Nabota' to Kuwait.
This contract marks Daewoong Pharmaceutical's fifth entry into the Middle East and its fourth entry among the six Gulf Cooperation Council (GCC) countries, following the United Arab Emirates (UAE), Saudi Arabia, and Qatar. The six GCC countries are recognized as the leading premium markets in the Middle East due to their high interest in aesthetics and plastic surgery.
Kuwait has a high per capita income of approximately $32,000, a well-developed medical infrastructure, and active exchanges with other Gulf countries, making it highly strategic with significant synergy potential. Daewoong Pharmaceutical plans to use Kuwait as a bridgehead to further expand Nabota's presence across all Gulf countries.
Among domestic toxin brands, Daewoong Pharmaceutical has entered the largest number of Middle Eastern countries with its botulinum toxin products, accelerating its efforts to penetrate the local market. The company emphasizes that it is not only supplying products, but also enhancing the procedural capabilities of Middle Eastern medical professionals, thereby increasing both patient satisfaction and service quality. Daewoong Pharmaceutical is continuously conducting academic activities on various topics, such as its proprietary combination procedures and the Nabolift technique, through conferences, webinars, and training programs. At the same time, it is strengthening the scientific evidence for Nabota's superior quality and safety through clinical research collaborations with local medical professionals.
Yoon Junsu, Head of the Nabota Business Division at Daewoong Pharmaceutical, stated, "This entry into Kuwait will help Nabota establish itself as a leading brand in the Middle Eastern premium toxin market and further strengthen our market strategy. Through differentiated academic activities based on clinical evidence and data, as well as the dissemination of our proprietary procedures, we will rapidly expand our presence throughout the Middle East."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
